IN2014KN01714A - - Google Patents
Info
- Publication number
- IN2014KN01714A IN2014KN01714A IN1714KON2014A IN2014KN01714A IN 2014KN01714 A IN2014KN01714 A IN 2014KN01714A IN 1714KON2014 A IN1714KON2014 A IN 1714KON2014A IN 2014KN01714 A IN2014KN01714 A IN 2014KN01714A
- Authority
- IN
- India
- Prior art keywords
- antibody
- cancer
- amino acid
- acid sequence
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012035342 | 2012-02-21 | ||
| PCT/JP2013/054312 WO2013125630A1 (fr) | 2012-02-21 | 2013-02-21 | Composition pharmaceutique pour le traitement et/ou la prévention du cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014KN01714A true IN2014KN01714A (fr) | 2015-10-23 |
Family
ID=49005808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1714KON2014 IN2014KN01714A (fr) | 2012-02-21 | 2013-02-21 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9260513B2 (fr) |
| EP (1) | EP2818481B1 (fr) |
| JP (1) | JP6187257B2 (fr) |
| KR (1) | KR102005308B1 (fr) |
| CN (1) | CN104114581B (fr) |
| AU (1) | AU2013223137B2 (fr) |
| BR (1) | BR112014021099A2 (fr) |
| CA (1) | CA2864999C (fr) |
| DK (1) | DK2818481T3 (fr) |
| ES (1) | ES2749672T3 (fr) |
| HU (1) | HUE046788T2 (fr) |
| IN (1) | IN2014KN01714A (fr) |
| MX (1) | MX363136B (fr) |
| PL (1) | PL2818481T3 (fr) |
| PT (1) | PT2818481T (fr) |
| RU (1) | RU2639522C2 (fr) |
| WO (1) | WO2013125630A1 (fr) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0911925B8 (pt) | 2008-08-05 | 2024-02-06 | Toray Industries | Método para detectar um câncer |
| KR101638490B1 (ko) * | 2008-08-05 | 2016-07-11 | 도레이 카부시키가이샤 | 암의 치료 및 예방용 의약 조성물 |
| MX340015B (es) * | 2010-02-04 | 2016-06-22 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| KR102041832B1 (ko) * | 2011-08-04 | 2019-11-08 | 도레이 카부시키가이샤 | 췌장암의 치료 및/또는 예방용 의약 조성물 |
| BR112014002616B1 (pt) | 2011-08-04 | 2022-01-18 | Toray Industries, Inc | Método para detectar câncer pancreático |
| PT2818483T (pt) | 2012-02-21 | 2017-10-09 | Toray Industries | Composição medicinal para tratamento e/ou prevenção de cancro |
| PT2832366T (pt) | 2012-03-30 | 2018-01-25 | Toray Industries | Composição farmacêutica para o tratamento e/ou a prevenção de cancro de vesícula biliar |
| KR102155531B1 (ko) * | 2012-03-30 | 2020-09-15 | 도레이 카부시키가이샤 | 간암의 치료 및/또는 예방용 의약 조성물 |
| RU2646466C2 (ru) | 2012-07-19 | 2018-03-05 | Торэй Индастриз, Инк. | Метод детекции рака |
| PL2876447T3 (pl) | 2012-07-19 | 2020-05-18 | Toray Industries, Inc. | Sposób wykrywania nowotworu |
| ES2704909T3 (es) | 2013-08-09 | 2019-03-20 | Toray Industries | Composición farmacéutica para el tratamiento y/o la prevención del cáncer |
| KR102726248B1 (ko) | 2016-07-07 | 2024-11-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| KR20240005247A (ko) | 2016-10-28 | 2024-01-11 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| JP7342701B2 (ja) * | 2018-03-30 | 2023-09-12 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| AU2020291014B2 (en) | 2019-06-13 | 2025-06-05 | Bolt Biotherapeutics, Inc. | Aminobenzazepine compounds, immunoconjugates, and uses thereof |
| JP2022549510A (ja) | 2019-09-30 | 2022-11-25 | ボルト バイオセラピューティクス、インコーポレーテッド | アミド結合したアミノベンズアゼピン免疫複合体、及びその使用 |
| CA3155077A1 (fr) | 2019-10-25 | 2021-04-29 | Romas Kudirka | Immunoconjugues de thienoazepine et leurs utilisations |
| US20230139178A1 (en) * | 2020-03-12 | 2023-05-04 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| CA3175127A1 (fr) * | 2020-03-12 | 2021-09-16 | Toray Industries, Inc. | Medicament pour le traitement et/ou la prevention du cancer |
| KR20220152318A (ko) * | 2020-03-12 | 2022-11-15 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| BR112022018161A2 (pt) | 2020-03-12 | 2022-10-25 | Toray Industries | Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer |
| WO2021182572A1 (fr) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | Médicament pour le traitement et/ou la prévention du cancer |
| CN115996756A (zh) | 2020-05-08 | 2023-04-21 | 博尔特生物治疗药物有限公司 | 弹性蛋白酶底物肽连接子免疫缀合物及其用途 |
| CN116234586A (zh) | 2020-08-13 | 2023-06-06 | 博尔特生物治疗药物有限公司 | 吡唑并氮呯免疫缀合物及其用途 |
| WO2022270523A1 (fr) | 2021-06-23 | 2022-12-29 | 東レ株式会社 | Médicament pour le traitement et/ou la prévention du cancer |
| AU2022298240A1 (en) | 2021-06-23 | 2024-01-18 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| AU2022316644A1 (en) | 2021-07-27 | 2024-02-29 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| CN117677398A (zh) | 2021-07-27 | 2024-03-08 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
| WO2023008459A1 (fr) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | Médicament pour le traitement et/ou la prévention du cancer |
| MX2024002571A (es) | 2021-09-03 | 2024-03-20 | Toray Industries | Composicion farmaceutica para tratamiento y/o prevencion de cancer. |
| CN118475372A (zh) | 2021-10-29 | 2024-08-09 | 博尔特生物治疗药物有限公司 | 具有半胱氨酸突变抗体的tlr激动剂免疫缀合物及其用途 |
| KR20250031149A (ko) | 2022-06-30 | 2025-03-06 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| KR20250052364A (ko) | 2022-08-24 | 2025-04-18 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| AU2023329564A1 (en) | 2022-08-24 | 2025-02-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| EP4578457A1 (fr) | 2022-08-24 | 2025-07-02 | Toray Industries, Inc. | Composition pharmaceutique pour le traitement et/ou la prévention du cancer |
| WO2024048542A1 (fr) | 2022-08-30 | 2024-03-07 | 東レ株式会社 | Médicament pour le traitement et/ou la prévention du cancer |
| EP4582100A1 (fr) | 2022-08-30 | 2025-07-09 | Toray Industries, Inc. | Médicament pour le traitement et/ou la prévention du cancer |
| CN120302998A (zh) | 2022-12-23 | 2025-07-11 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
| WO2024173387A1 (fr) | 2023-02-14 | 2024-08-22 | Bolt Biotherapeutics, Inc. | Immunoconjugués d'aza-benzazépine et leurs utilisations |
| WO2024186626A1 (fr) | 2023-03-03 | 2024-09-12 | Bolt Biotherapeutics, Inc. | Immunoconjugués d'agonistes de sting aza-bicycliques et leurs utilisations |
| JPWO2024204325A1 (fr) | 2023-03-28 | 2024-10-03 | ||
| AU2024246833A1 (en) | 2023-03-31 | 2025-09-25 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| AU2024339683A1 (en) | 2023-09-13 | 2026-03-26 | Toray Industries, Inc. | Pharmaceutical composition for treating, preventing and/or diagnosing cancer |
| WO2026055185A1 (fr) | 2024-09-04 | 2026-03-12 | Bolt Biotherapeutics, Inc. | Immunoconjugués agonistes sting et leurs utilisations |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| CA2194907A1 (fr) | 1994-07-13 | 1996-02-01 | Kouji Matsushima | Anticorps humain reconstitue contre l'interleukine-8 humaine |
| US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
| US6677436B1 (en) | 1998-04-03 | 2004-01-13 | Chugai Seiyaku Kabushiki Kaisha | Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody |
| US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
| CN100419079C (zh) | 1998-07-14 | 2008-09-17 | 科里克萨有限公司 | 用于治疗和诊断前列腺癌的组合物和方法 |
| US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6335170B1 (en) | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
| EP1187915A2 (fr) | 1999-04-02 | 2002-03-20 | Corixa Corporation | Composes utilises dans la therapie et le diagnostic du cancer du poumon et methodes d'utilisation |
| US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| JP2003528587A (ja) | 1999-10-29 | 2003-09-30 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ２７個のヒト分泌タンパク質 |
| US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| PL366626A1 (en) | 2000-03-29 | 2005-02-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| CN1487996B (zh) | 2000-11-30 | 2010-06-16 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
| US20040236091A1 (en) | 2001-03-28 | 2004-11-25 | Chicz Roman M. | Translational profiling |
| WO2002083070A2 (fr) | 2001-04-10 | 2002-10-24 | Corixa Corporation | Composes pour l'ummunotherapie et le diagnostic du cancer du colon et methodes d'utilisation associees |
| US7476536B2 (en) | 2001-05-11 | 2009-01-13 | Kirin Pharma Kabushiki Kaisha | Artificial human chromosome containing human antibody a light chain gene |
| AU2002311909A1 (en) | 2001-05-11 | 2002-11-25 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| EP2388265A1 (fr) | 2002-02-22 | 2011-11-23 | Genentech, Inc. | Compositions et procédés pour le traitement de maladies liées au système immunitaire |
| US20050003390A1 (en) | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
| US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| EP1572116A4 (fr) | 2002-11-26 | 2007-12-12 | Genentech Inc | Compositions et procedes destines au traitement de maladies de nature immune |
| WO2004076682A2 (fr) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Cibles destinees a reguler la croissance cellulaire et destinees a des methodes de diagnostic |
| WO2004097051A2 (fr) | 2003-04-29 | 2004-11-11 | Wyeth | Techniques et appareils de diagnostic de lam et de mds |
| EP1639090A4 (fr) | 2003-06-09 | 2008-04-16 | Univ Michigan | Compositions et methodes de traitement et de diagnostic du cancer |
| WO2005007830A2 (fr) | 2003-07-14 | 2005-01-27 | Mayo Foundation For Medical Education And Research | Procedes et compositions pour diagnostic, stadage et pronostic du cancer de la prostate |
| US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
| WO2005116076A2 (fr) | 2004-01-26 | 2005-12-08 | Debiovision Inc. | Polypeptides specifiques aux tumeurs et leurs utilisations |
| EP2332990A1 (fr) | 2004-03-19 | 2011-06-15 | Imclone LLC | Anticorps de récepteur de facteur de croissance anti-épidermique humain |
| HRP20110657T1 (hr) | 2004-03-30 | 2011-10-31 | Glaxo Group Limited | Imunoglobulin koji se veže na osm |
| WO2005100998A2 (fr) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Marqueurs membranaires destines a etre utilises pour le diagnostic et le traitement du cancer |
| WO2006002378A2 (fr) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determination de genes associes au cancer et de cibles therapeutiques utilisant des methodes de cytogenetique moleculaire |
| CA2592177A1 (fr) | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Dosage fixe d'anticorps anti-her |
| CN101120252A (zh) | 2005-02-18 | 2008-02-06 | 儿童医疗中心有限公司 | 作为生物标记物用于上皮来源的癌症的诊断和预后的cyr61 |
| AU2006223374B2 (en) | 2005-03-11 | 2011-07-21 | Aspira Women’s Health Inc. | Biomarkers for ovarian cancer and endometrial cancer: hepcidin |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| EP1991701A4 (fr) | 2006-02-14 | 2010-03-17 | Dana Farber Cancer Inst Inc | Compositions, kits, et procédés pour identifier, évaluer, prévenir et traiter un cancer |
| WO2008073162A2 (fr) | 2006-08-17 | 2008-06-19 | Cell Signaling Technology, Inc. | Sites d'acétylation de lysine |
| US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US7615349B2 (en) | 2006-09-07 | 2009-11-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
| WO2008059252A2 (fr) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Procédés et composition de récepteurs des lymphocytes t qui reconnaissent l'antigène 5t4 |
| JP5663834B2 (ja) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
| NZ602675A (en) | 2008-03-18 | 2014-03-28 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| KR101638490B1 (ko) | 2008-08-05 | 2016-07-11 | 도레이 카부시키가이샤 | 암의 치료 및 예방용 의약 조성물 |
| CN102112146B (zh) | 2008-08-05 | 2014-03-12 | 东丽株式会社 | 免疫诱导剂 |
| BRPI0911925B8 (pt) | 2008-08-05 | 2024-02-06 | Toray Industries | Método para detectar um câncer |
| ES2622487T3 (es) | 2009-08-19 | 2017-07-06 | Merck Patent Gmbh | Anticuerpos para la detección de complejos de integrina en material FFPE |
| SG178925A1 (en) | 2009-09-22 | 2012-04-27 | Volker Sandig | Process for producing molecules containing specialized glycan structures |
| RU2418587C1 (ru) * | 2010-01-21 | 2011-05-20 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") | Способ лечения злокачественных опухолей головного мозга |
| BR112012018943A8 (pt) * | 2010-02-04 | 2017-12-19 | Toray Industries | medicamento e método para o tratamento e/ou prevenção de um câncer |
| KR101842893B1 (ko) | 2010-02-04 | 2018-03-28 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| HUE025678T2 (en) | 2010-02-04 | 2016-04-28 | Toray Industries | A pharmaceutical composition for the treatment and / or prevention of cancer |
| RU2598258C2 (ru) | 2010-02-04 | 2016-09-20 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
| MX342291B (es) | 2010-02-04 | 2016-09-23 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| MX340015B (es) | 2010-02-04 | 2016-06-22 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| WO2012005550A2 (fr) | 2010-07-08 | 2012-01-12 | 강원대학교산학협력단 | Composition pharmaceutique pour le traitement d'un carcinome de la vésicule biliaire et méthode d'inhibition de la croissance et des métastases d'un carcinome de la vésicule biliaire et le traitement d'un carcinome de la vésicule biliaire à l'aide de celle-ci |
| CA2806157C (fr) | 2010-07-26 | 2016-11-22 | Les Laboratoires Servier | Methodes et compositions pour une therapie contre le cancer du foie |
| JP5545105B2 (ja) | 2010-08-04 | 2014-07-09 | 株式会社ジェイテクト | トロイダル型無段変速機のディスクの研磨方法およびトロイダル無段変速機のディスクの研磨装置 |
| JP6070191B2 (ja) | 2011-08-04 | 2017-02-01 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| KR102041832B1 (ko) | 2011-08-04 | 2019-11-08 | 도레이 카부시키가이샤 | 췌장암의 치료 및/또는 예방용 의약 조성물 |
| BR112014002616B1 (pt) * | 2011-08-04 | 2022-01-18 | Toray Industries, Inc | Método para detectar câncer pancreático |
| PT2832366T (pt) * | 2012-03-30 | 2018-01-25 | Toray Industries | Composição farmacêutica para o tratamento e/ou a prevenção de cancro de vesícula biliar |
| KR102155531B1 (ko) | 2012-03-30 | 2020-09-15 | 도레이 카부시키가이샤 | 간암의 치료 및/또는 예방용 의약 조성물 |
-
2013
- 2013-02-21 US US14/379,868 patent/US9260513B2/en active Active
- 2013-02-21 MX MX2014009747A patent/MX363136B/es unknown
- 2013-02-21 PT PT137511598T patent/PT2818481T/pt unknown
- 2013-02-21 KR KR1020147020831A patent/KR102005308B1/ko active Active
- 2013-02-21 PL PL13751159T patent/PL2818481T3/pl unknown
- 2013-02-21 WO PCT/JP2013/054312 patent/WO2013125630A1/fr not_active Ceased
- 2013-02-21 EP EP13751159.8A patent/EP2818481B1/fr active Active
- 2013-02-21 HU HUE13751159A patent/HUE046788T2/hu unknown
- 2013-02-21 DK DK13751159.8T patent/DK2818481T3/da active
- 2013-02-21 RU RU2014138039A patent/RU2639522C2/ru active
- 2013-02-21 CA CA2864999A patent/CA2864999C/fr active Active
- 2013-02-21 AU AU2013223137A patent/AU2013223137B2/en active Active
- 2013-02-21 CN CN201380009166.3A patent/CN104114581B/zh active Active
- 2013-02-21 IN IN1714KON2014 patent/IN2014KN01714A/en unknown
- 2013-02-21 BR BR112014021099-3A patent/BR112014021099A2/pt not_active Application Discontinuation
- 2013-02-21 ES ES13751159T patent/ES2749672T3/es active Active
- 2013-02-21 JP JP2013512279A patent/JP6187257B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104114581B (zh) | 2018-11-30 |
| MX2014009747A (es) | 2014-11-14 |
| HUE046788T2 (hu) | 2020-03-30 |
| DK2818481T3 (da) | 2019-10-14 |
| US20150044221A1 (en) | 2015-02-12 |
| WO2013125630A1 (fr) | 2013-08-29 |
| AU2013223137A1 (en) | 2014-09-11 |
| EP2818481A4 (fr) | 2015-10-07 |
| CN104114581A (zh) | 2014-10-22 |
| AU2013223137B2 (en) | 2017-10-19 |
| JP6187257B2 (ja) | 2017-08-30 |
| EP2818481B1 (fr) | 2019-08-07 |
| KR102005308B1 (ko) | 2019-07-30 |
| PL2818481T3 (pl) | 2020-02-28 |
| EP2818481A1 (fr) | 2014-12-31 |
| CA2864999C (fr) | 2020-06-30 |
| JPWO2013125630A1 (ja) | 2015-07-30 |
| KR20140130670A (ko) | 2014-11-11 |
| CA2864999A1 (fr) | 2013-08-29 |
| PT2818481T (pt) | 2019-10-25 |
| BR112014021099A2 (pt) | 2020-12-01 |
| RU2014138039A (ru) | 2016-04-10 |
| RU2639522C2 (ru) | 2017-12-21 |
| US9260513B2 (en) | 2016-02-16 |
| ES2749672T3 (es) | 2020-03-23 |
| MX363136B (es) | 2019-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014KN01713A (fr) | ||
| IN2014KN01714A (fr) | ||
| IN2014KN01716A (fr) | ||
| IN2014KN01715A (fr) | ||
| MX351682B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX351414B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. | |
| MX340014B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012008998A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012009000A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX360671B (es) | Composición farmacéutica para el tratamiento y/o prevención del cáncer. | |
| WO2017009843A3 (fr) | Compositions, articles de fabrication et procédés pour traiter le cancer | |
| NZ713461A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
| NZ761006A (en) | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema | |
| MX357965B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar. | |
| MY167232A (en) | Polypeptides binding to human complement c5 | |
| IN2014DN09963A (fr) | ||
| NZ721015A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
| GB201118201D0 (en) | Novel peptides | |
| AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
| WO2014039074A3 (fr) | Compositions thérapeutiques et méthodes associées | |
| MX362058B (es) | Péptido pntx(19) sintético, composición farmacéutica y uso. | |
| MX2018011133A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. |